FDA Panel Gives Humira the Nod for Colitis

(MedPage Today) — An FDA advisory panel has voted in favor of extending the use of adalimumab (Humira) to ulcerative colitis, which would give patients an additional biologic option for treatment — one they could inject themselves.

Post a Comment

Comments are closed.